L
Laurèl Rauschenbach
Researcher at University of Duisburg-Essen
Publications - 71
Citations - 491
Laurèl Rauschenbach is an academic researcher from University of Duisburg-Essen. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 39 publications receiving 218 citations. Previous affiliations of Laurèl Rauschenbach include University of Bonn & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.
Journal ArticleDOI
Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.
Roman Reinartz,Shanshan Wang,Sied Kebir,Daniel J. Silver,Anja Wieland,Tong Zheng,Marius D. Kupper,Laurèl Rauschenbach,Rolf Fimmers,Timothy M. Shepherd,Daniel Trageser,Andreas Till,Niklas Schäfer,Martin Glas,Axel M. Hillmer,Sven Cichon,Amy Smith,Torsten Pietsch,Ying Liu,Brent A. Reynolds,Anthony T. Yachnis,David W. Pincus,Matthias Simon,Oliver Brüstle,Dennis A. Steindler,Björn Scheffler +25 more
TL;DR: The data provide a previously unrecognized strategy for revealing functional consequences of intratumor heterogeneity by enabling predictive modeling of treatment-related subclone dynamics in human glioblastoma.
Journal ArticleDOI
Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
Niklas Schäfer,Niklas Schäfer,Gerrit H. Gielen,Laurèl Rauschenbach,Laurèl Rauschenbach,Sied Kebir,Andreas Till,Roman Reinartz,Matthias Simon,Pitt Niehusmann,Christoph Kleinschnitz,Ulrich Herrlinger,Torsten Pietsch,Björn Scheffler,Martin Glas +14 more
TL;DR: The high incidence of dissimilar target expression status in clinical samples from primary vs. recurrent GBM suggests clinically relevant heterogeneity along the course of disease.
Journal ArticleDOI
Secondary hemorrhagic complications in aneurysmal subarachnoid hemorrhage: when the impact hits hard.
Marvin Darkwah Oppong,Kathrin Buffen,Daniela Pierscianek,Annika Herten,Yahya Ahmadipour,Philipp Dammann,Laurèl Rauschenbach,Michael Forsting,Ulrich Sure,Ramazan Jabbarli +9 more
TL;DR: Antiplatelet therapy during (but not before) SAH increases the risk of ventriculostomy-associated bleedings, but without further impact on the course and outcome of SAH, and major SHCs present a rare sequela ofSAH.
Journal ArticleDOI
Regorafenib in patients with recurrent high-grade astrocytoma.
Sied Kebir,Laurèl Rauschenbach,Alexander Radbruch,Lazaros Lazaridis,Teresa Schmidt,Ann-Kathrin Stoppek,Daniela Pierscianek,Martin Stuschke,Michael Forsting,Ulrich Sure,Kathy Keyvani,Christoph Kleinschnitz,Björn Scheffler,Martin Glas +13 more
TL;DR: This retrospective study indicates a very poor performance of regorafenib in recurrent high-grade astrocytoma with a fairly high number of CTC°3 adverse events, and regorAFenib does not seem to bear a potential for infiltrative tumor growth promotion.